The biopharmaceutical company said its liquidity account held 65,000 shares and €973,620.20 in cash at June 30, 2026, after 3,200 buy trades and 2,721 sell trades in the first half.
GENFIT said the liquidity contract it has with Crédit Industriel et Commercial held 65,000 shares and €973,620.20 in cash as of June 30, 2026. During the first half of 2026, buy-side trading totaled 1,598,594 shares for €12,813,126.30 across 3,200 trades, while sell-side trading totaled 1,549,771 shares for €12,677,508.21 across 2,721 trades. The company recalled that when the contract was signed, the liquidity account held 27,911 shares and €769,849.43. GENFIT, listed on Euronext Paris under the ticker GNFT, focuses on rare and life-threatening liver diseases. The company said its portfolio includes programs in Acute on-chronic Liver Failure and related conditions, as well as other serious diseases, and noted that Iqirvo (elafibranor) received accelerated approval in 2024 from the FDA, EMA and MHRA for second-line treatment of Primary Biliary Cholangitis and is now marketed in several countries.